The intergroup rhabdomyosarcoma study‐II

  title={The intergroup rhabdomyosarcoma study‐II},
  author={Harold M. Maurer and Edmund A. Gehan and Mohan S. Beltangady and William M. Crist and Paul S. Dickman and Sarah S. Donaldson and Christopher Fryer and Denman Hammond and Daniel M. Hays and J Herrmann and Ruth M. Heyn and Patt Jones and Walter Lawrence and William A. Newton and Jorge A. Ortega and Abdelsalam H. Ragab and Richard Beverly Raney and Frederick B. Ruymann and Edward H. Soule and Melvin Tefft and Bruce L. Webber and Eugene S. Wiener and Moody D. Wharam and Teresa J. Vietti},
Background. Intergroup Rhabdomyosarcoma Study (IRS)‐II, (1978–1984) had the general goals of improving the survival and treatment of children with rhabdomyosarcoma (RMS). 
Primary renal sarcomas in the Intergroup Rhabdomyosarcoma Study Group (IRSG) experience, 1972–2005: A report from the Children's Oncology Group
Clinical and pathologic characteristics and outcome of patients with renal sarcomas are described.
Results of treatment of patients with superficial facial rhabdomyosarcomas on protocols of the Intergroup Rhabdomyosarcoma Study Group (IRSG), 1984–1997
We analyzed the outcome of 47 patients with superficial facial rhabdomyosarcoma (RMS) treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols‐III, ‐IV‐Pilot, and ‐IV.
Adult rhabdomyosarcoma
Childhood rhabdomyosarcoma (RMS) has a relatively good prognosis. Outcome for adults with this disease is poorly documented due to its rarity.
Results in patients with cranial parameningeal sarcoma and metastases (Stage 4) treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols II–IV, 1978–1997: Report from the Children's Oncology Group
Determine outcome of patients with cranial parameningeal sarcoma and concurrent metastases treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols II–IV.
Imaging findings in noncraniofacial childhood rhabdomyosarcoma
This paper focuses on imaging for diagnosis, staging, and follow-up of noncraniofacial RMS, the most common soft-tissue sarcoma of childhood.
Embryonal rhabdomyosarcoma with metastases confined to the lungs: Report from the CWS Study Group
Embryonal rhabdomyosarcoma [RME] is the most common pediatric soft tissue sarcoma and the prognosis remains poor for metastatic disease.
Rhabdomyosarcoma in infants younger than 1 year
Rhabdomyosarcoma (RMS), the most common soft‐tissue sarcoma in children, occurs less commonly in infants than in older children, and poorer outcomes have been reported for infants diagnosed with RMS.
What constitutes optimal therapy for patients with rhabdomyosarcoma of the female genital tract?
Factors affecting outcome for rhabdomyosarcoma of the female genital tract in patients treated on I–IV protocols I-IV were evaluated to define optimal therapy.
Is alveolar histotype a prognostic factor in paratesticular rhabdomyosarcoma? The experience of Italian and German Soft Tissue Sarcoma Cooperative Group
To ascertain whether alveolar histology retains its adverse prognostic role in the subset of paratesticular rhabdomyosarcoma (RMS) patients, generally characterized by a very good outcome.


Histopathology of childhood sarcomas, Intergroup Rhabdomyosarcoma Studies I and II: clinicopathologic correlation.
  • W. Newton, E. Soule, H. Maurer
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1988
There was close agreement between the review committee and institutional pathologists in the diagnosis of RMS, but not in the specific types, particularly Alv RMS and STI, and the prognosis varied by histology, with Botr having the best, Alv R MS andSTI the worst, and Emb RMSand EOE an intermediate prognosis.
Questionable role of CNS radioprophylaxis in the therapeutic management of childhood rhabdomyosarcoma with meningeal extension.
It is concluded that CNS prophylaxis with radiotherapy is questionable in the management of childhood RMSA with meningeal extension.
Prognostic factors in 281 children with nonmetastatic rhabdomyosarcoma (RMS) at diagnosis.
Pretreatment characteristics of 281 children with nonmetastatic rhabdomyosarcoma, included in the registry of the International Society of Pediatric Oncology (SIOP) between January 1975 and December
Results of intensive therapy in children with localized alveolar extremity rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study.
  • R. Heyn, M. Beltangady, H. Maurer
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1989
Despite the limited statistical evidence, there is some indication that intensive therapy improved the prognosis of children with localized alveolar rhabdomyosarcoma (RMS).
Prognostic significance of staging factors of the UICC staging system in childhood rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS-II).
A retrospective assessment of the relationship of these pretreatment observations to survival experience indicates definite prognostic significance for all of the individual factors used on the International Union Against Cancer (UICC) pretreatment staging system except clinical status of regional nodes.
Treatment of high-risk sarcomas in children and young adults: analysis of local control using intensive combined modality therapy.
An intensive treatment protocol was designed that integrates five cycles of chemotherapy with vincristine, doxorubicin, and cyclophosphamide (VADRIAC) plus radiation therapy to the primary tumor, bone, and soft tissue metastases and 68 of 75 patients achieved complete response.
Improved prognosis with intensive treatment of children with cranial soft tissue sarcomas arising in nonorbital parameningeal sites. A report from the intergroup rhabdomyosarcoma study
In this report, the prognoses of two groups of patients with nonorbital cranial parameningeal sarcoma are compared: 95 patients treated before modification of the protocol in December 1977 with chemotherapy and nonintensive meningeal radiotherapy (preintensive group) and 68 patients treated subsequently with intensive meningealing radiotherapy and chemotherapy (intensive group).